Shasun Pharmaceuticals has temporarily suspended the production at its Cuddalore API facility on account of fire accident in one of the manufacturing blocks of the said unit. The company is working with the Government authorities to resume operations at the earliest. Though, there will be no material impact on the revenue of the group during the current financial year.
Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities.
